Departments, Centers, & Programs:
Neuroendocrine and Pituitary Tumor Clinical Center
55 Fruit Street
Boston, MA 02114-2696
- MD, New York University School of Medicine
- Residency, New York University School of Medicine
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
- Endocrinology, Diabetes and Metabolism, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
My study of how 100 patients with acromegaly came to diagnosis targeted education on this rare disease to professionals who most likely encounter it. I investigated a long acting somatostatin analog with a novel delivery system. I have contributed to several reviews on acromegaly and hyperprolactinemia and edited chapters on these topics. I have created an acromegaly database, including longitudinal data in over 350 patients, which will improve clinical practice strategies and serve as a resource for clinical investigation and as a model for database construction. I received an investigator initiated award to study long term treatment of acromegaly with somatostatin analogs.
Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.
Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C, Hemphill L, Nachtigall L, Loeffler J, Swearingen B, Biller BM, Klibanski A. J Clin Endocrinol Metab. 2010 Feb;95(2):567-77. Epub 2010 Jan 8.
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-na?ve patients with acromegaly.
Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, Chang S; SALSA Study Group. Pituitary. 2010 Jun;13(2):115-22.